by GOAI

由GOAI生成

Share To

分享到

Sanofi reported a 2.5% decline in vaccine sales for the year 2025, with nearly all immunization products experiencing reduced demand. The pharmaceutical company disclosed the downturn amidst ongoing challenges in the global vaccine market. Despite this setback, Sanofi’s CEO Paul Hudson reiterated his commitment to advancing vaccine development as part of the company’s broader public health mission..

赛诺菲报告称，2025年疫苗销售额下降了2.5%，几乎所有免疫产品的需求都有所减少。这家制药公司在全球疫苗市场持续面临挑战的情况下披露了这一下滑。尽管遭遇此挫折，赛诺菲首席执行官保罗·哈德森重申了他对推进疫苗开发的承诺，作为公司更广泛的公共卫生使命的一部分。

The decrease in sales marks another challenging year for Sanofi’s vaccine division, which has faced fluctuating demand across its portfolio. The company did not specify which vaccines were most affected by the decline but indicated that the drop was widespread across its immunization offerings. In response to these figures, Hudson emphasized Sanofi’s dedication to continuing its work in vaccine innovation and production, describing it as a critical contribution to public health efforts worldwide..

销售额的下降标志着赛诺菲疫苗部门又一个充满挑战的年份，该部门在其产品组合中面临需求波动。公司并未具体说明哪些疫苗受下降影响最大，但指出其免疫产品系列的下滑是普遍的。针对这些数据，哈德森强调了赛诺菲致力于继续在疫苗创新和生产方面的工作，称其为对全球公共卫生努力的关键贡献。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: January 29, 2026

日期：2026年1月29日

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 保留所有权利。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章